

To.

BSE Limited, 25, P. J. Towers, Dalal Street. Mumbai - 400 001

Ref: Company Scrip Code: 532834

Listing Department,

National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex,

Bandra (East), Mumbai- 400051

Ref: Symbol: CAMLINFINE || Series: EQ

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

The Board of Directors of the Company at its meeting held today i.e., 24th May, 2019, inter alia, has taken note and approved the following:

- 1. The Audited Financial Results (standalone and consolidated) for the quarter and year ended 31st March, 2019. The audited results along with audit reports are enclosed herewith as Annexure-1.
- 2. Appointment of Mr. Amol Shah (DIN: 00171006) as Independent Non-Executive Director at the ensuing 26th Annual General Meeting of the Company. Disclosure related to the same is enclosed herewith as Annexure -2.
- 3. Resignation tendered by Mr. Ajit Deshmukh (DIN: 00203706), Non-Executive Director from the directorship of the Company on personal grounds w.e.f. 24th May, 2019 from the conclusion of this meeting.
- 4. The Notice of the 26th Annual General Meeting scheduled to be held on Friday, 02nd August, 2019 inter alia to consider and adopt the audited financial statements (including the consolidated financial statements) of the Company for the financial year ended 31st March, 2019 and the reports of the Board of Directors and Auditors thereon.

5. Closure of the Register of Member and Share Transfer Books of the Company from 27th August, 2019 to 02nd August, 2019 (both days inclusive) for taking record of the Members of the Company for the purpose of 26th Annual General Meeting.

The meeting of Board of Directors commenced at 01.30 pmand concluded at 06.30 pm. Kindly take the above information on records.

Encl.: a/a.

Thanking You,

For Camlin Fine Sciences Limited

(Rahul Sawale)

Group Company Secretary

Registered Office:

Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400093, India. CIN: L74100MH1993PLC075361







Recovered from expectations Total incomes			STANDALONE		STANDALON	NE				(Rs.i	(Rs.in Lakh, except per share data)	Der sharo d
Color income Colo		PARTICULARS	_	UARTER EN	DED		ENIDER			SOLH	ED	n annua m.d
			31.03.2019	31.12.2018	21 02 2010	TEME	ENDED	0	UARTER END	ŒD	YEAR	YEAR ENDED
Divinite from operation 17,151.16 14,597.66 12,151.6 14,157.6 12,151.6 14,157.6 12,151.6 14,157.6 12,151.6 14,157.6 12,151.6 14,157.6 12,151.6 14,157.6 12,151.6 14,157.6 12,151.6 14,157.6 12,151.6 14,157.6 12,151.6 12,151.6 14,157.6 12,151.6 14,157.6 12,151.6 14,157.6 12,151.6 14,157.6 12,151.6 14,157.6 12,151.6 14,157.6 12,151.6 14,157.6 12,151.6 14,157.6 12,151.6 14,157.6 12,	1		(Audited)	_	_	-	31.03.2018	31.03.2019	31.12.2018	31.03.2018	31.02.2019	24 000 000
Total income	-			-	_	+	(Audited)	(Audited)	(Unaudited)	-	(Anditod)	31.03.2018
Court of matter the country of the	N M		17,151.18	14	12		40,502.79	26 803 52	24 4 4 9 0 0		(Danmed)	(Audited)
Color of materials communed 1270-64 1175-55 880-65 575-64 1475-55 178-74 1475-55 178-74 1475-55 178-74 177-74 17		- 1	17,334.74	15	1		923.06		24,139.88	23,168.70	89,216.67	72,276.17
Purchase of sixet, in real streaming 127.54	7	Cost of materials				55,896.94	41,425.85	27,263.47	24,223,39	24	1,378.73	864.36
Contage in inventories of finished goods/NIP/stack in tade 25/22 288.57 288.57 228.58 238.59 238.50 238.		Purchase of stock in trade	12,276.49			39 570 84	00 000 30				06,295,40	73,140.53
Excise days a convention of person of the pe		Changes in inventories of finished acceleration		98.55		547.65	23,947.19	15,308.58	11,661.86	11,078.08	46,928.06	39,382,78
Financy core benefits expense S66.75 611.89 S85.7 27.866 27.182		Excise duty		(203.47)		748.42	2,051.54	(38.80)	287.42	2,539.50	2,617.41	3,096.56
Figures cess Section Perceives Section Perceive Section Perceives Section Perceive Sectio		Employee benefits expense	1	,			211.01	(annual)	00.00	(481.72)	(2,065.19)	(234.87)
Chief response Chie		Finance costs	566.75	611.89		2,266,19	2 080 55		,	ı	ı.	215.76
Profit(Loss) bridges above at the period (3-4) 17,093-6 17,0		Other expenses	224.84	165.01	618,32	2,034.37	2,362,32	736 97	2,261.03	2,041.07	8,788.52	7,286.57
Profit(Loss) petere at a second (3-4) 285.09		Total Evidence	2,696.65	3 542 62	221.13	908.82	906.15	731.29	47.03.74	415.66	3,670.73	2,835,39
Particul (Loss) before tax (Sq.) Particul (Loss		D-Citie	17,039.65	16.156.70	12 550 16	8,402.02	7,315.23	7,249.56	7,630,38	6 949 36	2,899.32	2,665.42
Share of posity (loss) of associate SSS-56 (1,022.29) 792.32 1,518.63 (1,508.69) (67.33) (15.33.70) (1.98.34) (7.92.32) (1,523.64) (6.92.33) (1,523.64) (5.92.34) (5.92.36) (5			295.09	(1 022 30)	OT-mood-	34,478.31	43,232.75	26,591.58	24,383.17	23,520.90	88 920 24	77,705,71
Profit (Lass) before tax (8-6) 120 1418.63 1418.64 165.69 1418.64 165.69 165.64 165.69 165.64 165.		Share of profit/ (loss) of associate		(67077012)	/92.32	1,418.63	(1,806.90)	621.89	(159.78)	515 63	a de la constante de la consta	70,230.32
Tax Express		Profit / (Loss) before tax (5-6)				,		(5.88)	(0.00)	20,516	1,6/5.16	(3,089.79)
Profit (Las) for the period (7-s) Profit (1-s) for		Tax Expenses	295.09	(1,022.29)	792.32	1,418.63	(1.806.90)	(0000)	(0.02)	18.84	(5.88)	17.16
Profit/Loss for the period (7-s) 78.34 78.05 78.35		- Current tax					(ac nanda)	10.000	(159.80)	534.66	1,669.28	(3,072.63)
Proff()Los) for the period (7-9) Part		- Deferred tax	83.47	(290.30)	2.	320.41		76871	100 000			
Protificación for the period (7-8) for the period (7-10) for the comprehensive income articlusible to: Protificación profit or loss Profit or			29.77	(198.34)	670.25	25.40	(389.03)	(232.58)	(8.93)	167.36	1,582.98	857.11
Chems that will not be reclassified to profit or ross Remeasturements of defined benefit plans 1.270 (48.63) 3.776 (4.630) 18.66 12.70 (48.63) 3.776 (4.630) 18.66 12.70 (48.63) 3.776 (4.630) 16.18 (4.630) 16.		From (Loss) for the period (7-8)	265 32	(533 (1)	670.25	345.81	(389.03)	36.13	(80.97)	960 54	(214.28)	(1,532.52)
Herns that will not be redusified to profit or loss 12.70 (48.63) 37.76 (46.20) 18.66 12.70 (48.63) 37.76 (46.20) 16.67 (12.53) 16.18 (6.23) 16.18 (6.23) (4.44) 16.67 (12.53) 16.18 (6.23) (4.44) 16.67 (12.53) 16.18 (6.23) (4.44) 16.67 (12.53) 16.18 (6.23) (4.44) 16.67 (12.53) 16.18 (6.23) (4.44) (6.23) (4.44) (6.23) (4.44) (6.23) (4.44) (6.23) (4.44) (6.23) (4.44) (6.23) (4.44) (6.23) (4.44) (6.23) (4.44) (6.23) (4.44) (6.23) (4.24)		_		(carcec)	122.07	1,072.82	(1,417.87)	629.88	(78 63)	Table Con	1,305.70	(675.41)
Profit of loss Profit or loss Prof		Items	12.70	(48 63)	24.46				(60.03)	(425.88)	300.58	(2,397.22)
Exchange differences on translating the financial Exchange of translating the financial Exchange of translating the financial Exchange differences on translating the financial income bax relating to hems that will be reclassified to profit of the period (9+10) 273.88 (365.61) 147.28 134.27 (149.84) 244.09 (231.71) 169.62 Fordit / (loss) attributable to: 263.28 263.65 112.07 1,072.82 (303.64) 272.22 (203.64) 23.72 Other comprehensive income attributable to: 263.28 236.56 112.07 1,072.82 (147.87) 272.22 (203.64) 23.72 (115.96) Owners of the Company Non-controlling interests of the Company Non-controlling interests income attributable to: 273.28 (365.61) 147.28 1,042.70 (1,405.44) 1,042.56 (67.00) 292.28 Entitity be exclased from amundiscol 273.28 (365.61) 1,212.30 (1,405.44) 1,042.56 (67.00) 292.28 Entitity be exclased from amundiscol 273.28 (34.48)		to profit or loss	(4.44)	16.67	(12.55)	(46.30)	18.66	12.70	(48.63)	37.76	(46.30)	18 66
Exchange of trorego nor translating the financial statements of foreign operations or translating the financial statements of foreign operations		Items					(0.23)	(4.44)	16.67	(12.55)	16.18	(6.23)
Deceme in x relating to lower that will be reclassified to RS 26 RS 25		Exchange differences on translating the financial		,								
Other comprehensive income Total comprehensive income Total comprehensive							,	475.16	(631.64)	851.99	133.15	1,828.71
Total comprehensive income for the period (9-10) 273.58 (565.61) 147.28 15.27 (4.415.87) 12.43 314.21 (442.88) 585.50 Profit / (loss) attributable to:		Other comprehensive income			p)			(169.21)	220.72	(281.70)	(49.70)	(604 63)
Profit / (loss) attributable to: 273.88 (365.61) 147.28 1,042.70 (1,405.44) 944.09 585.50 Owners of the Company Non-controlling interests 100.22 (1,417.87) 272.22 (203.56) (30.92) Other comprehensive income attributable to: 8.26 (31.50) 25.21 (30.12) 1,072.82 (1,417.87) 272.22 (203.56) (30.92) Owners of the Company Non-controlling interests 8.26 (31.50) 25.21 (30.12) 124.33 315.34 (443.44) 559.17 Owners of the Company 273.38 (56.56.1) 147.28 1,042.70 (1,410.54) 1,042.56 (67.00) 56.33 Non-controlling interests 1212.24 1,212.30 1,212.30 (1,410.54) 1,042.56 (67.00) 56.33 Paid-up Equity Share Capital (Face Value Re.1)- per share) 1,212.24 1,212.30 1,212.30 1,212.30 1,212.30 1,212.30 1,212.30 1,212.30 1,212.30 1,212.30 1,212.30 1,212.30 1,212.30 1,212.30 1,212.30 </td <td></td> <td>Total comprehensive income for the norical (92.10)</td> <td>8.26</td> <td>(31.96)</td> <td>25.21</td> <td>(30.12)</td> <td>12.43</td> <td>314.21</td> <td>100 000)</td> <td></td> <td></td> <td></td>		Total comprehensive income for the norical (92.10)	8.26	(31.96)	25.21	(30.12)	12.43	314.21	100 000)			
Decease Dece		Profit (1)	273.58	(265.61)	147.28	1.042.70	(1 405 AA)		(447.98)	595.50	53.33	1,236.51
Other comprehensive income atributable to: 203.50 (30.99) (30.99) (30.99) (30.19) (30.12) (30.12) (30.12) (30.19) (30.99) (265.32	(533.65)	122.07	1.072.82	(1,417,07)	944.09	(521.71)	169.62	353.91	(1,160.71)
Non-controlling interests Total comprehensive income attributable to: Total comprehensive income attributable		Other comprehensive income attributable to:	í		,		-	(97.34)	(203.56)	(309.92)	57.72	(2,964.31) 567.09
Total comprehensive income attributable to: Class		_	8.26	(31.96)	25.21	(30.12)	12.43	315 34				
Non-combrolling interests 23.38 (56.56.1) 147.28 1.042.54 (1.405.44) 1.042.56 (6f.70.0) 2.92.55 Eurnings per Share (EPS) of Re.1/-each) (not amnualised) 0.22 (0.44) 0.76 0.88 (1.67) 0.80 (1.27) 0.40 (1.75) 0.80 (1.75) 0.		Total comprehensive income attributable to: Owners of the Company		,		,		(1.13)	(443.44)	539.17	(2.66)	1,222.95
Share (EPS) (of Re.1/-each) (not annualised) 0.22 (0.44) (0.26) (0.44) (0.26) (0.44) (0.26) (0.44) (0.26) (0.44) (0.26) (0.44) (0.26) (0.44) (0.26) (0.44) (0.26) (0.44) (0.26) (0.26) (0.44) (0.26) (0.26) (0.27) (Non-controlling interests	273.58	(265.61)	147.28		(,405,44)	1.042 56	(647 00)			
(1,212,4) (100) annualised) 0.22 (0.44) (0.26) 0.88 (1.67) 0.60 (0.17) (0.66)		Paid-up Equity Share Capital (Face Value Re.17- per share)	1,212.54	1,212.54	1,212.30			(98.47)	125.29	(59.63)	240.20	(1,741.36) 580.65
0.22 0.44 0.26 0.88 0.88 0.157 0.60 0.177		Basic (Rs.)					7777	1,212.54			1,212,54	1,212.30
	7	Diluted (Rs.)	0.22	(0.44)	(0.26)	0.88	(1.67)	070		_	_	



Registered Office:
Camlin Fine Sciences Ltd. F/I I-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400093, India.
CIN: L74100MH1993PLC075361







FOR CAMLIN FINE SCIENCES LIMITED

Notes to financial results:

The above results which have published in accordance with Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements), 2015 have been reviewed by the Audit Committee and approved by the Board of the Companies Act, 2019. The Inhancial results are in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of dated Movements 30, 2015 that been modified to companies Act, 2013 read with Rule 3 of dated Movements 30, 2015 that been modified to comply with the requirements of SEBI's circular The figures for the quarters ended March 31 as reported in these results are needed with a separate standed March 31 as reported in these results are the halancing figures between addied figures in the years ended March 31 and the published year to date Figures upto the end of the third quarter and only when reviewed and not subjected to audit.

4 On April 01, 2018, the Company has applicable are standed March 31, 2019 is net of Goods and Service Tax (GST), however the sales for the year ended March 31, 2018 are gross of excise duty. The net revenue from operations (net of GST) excise duty) as applicable are standed below:

	0	YEAR ENDED		
COMPOSITOR	OUARTER ENDED		21 02 2010	31.03.2019 31.12.2016
9	YEAR ENDED		31.03.2019 31.03.2018	OTOWNS
STANDALON	QUARTER ENDED	91 12 2010	31.12.2018 31.03.2018	
SII		31.03.201	TOTTOGER	4
Particula				

 Audited
 (Unaudited)
 (Audited)
 (Audited)

22,914.02 87,843.44 71,229.65		31.03.2019 31.12.2018 31.03.2018 31.03.2019 31.03.2019 31.03.2019 31.03.2019	19 31.03.2018	d) (Audited)	(73.49)
914.02 87,84	IDATED	YE	2018 31.03.20	70 31 (Audite	
23,811.10 22,	CONSOLIDATED	QUARTER ENDED	(Audited) (Thandited) (Audited)	(Audi	(532.78)
20,47 1,40		QUAR	(Audited) (IIIn		(462.54)
O CONTRACTOR OF THE CONTRACTOR	YEAR ENDED	31.03.2018	(Audited)	279.13	279.13
under:	1	8 31.03.2019	(Audited)	78 281.14	8 281.14
orting period as under	ENDED	18 31.03.201	ed) (Audited	.64)	.64) 180.78
loss) for each repo	QUARTER ENDED	31.12.20	(Unaudit	374.86) (1,046	374.86) (1,046.64)
exchange gain /		31.0	(Auto		
ludes net foreign					
xpense above inclu				n/(loss)	for course
ther income / Other expense above includes net foreign exchange gain / (loss) for each reporting period as under: Particulars STANDALONE			Other Evenes	Total Exchange gain / (loss)	indalone finance costs for current

7 Sandalone finance costs for current year and current quarter includes exchange gain on revaluation of foreign currency borrowings amounting to Rs. 398.68 lakks and Rs. 112.65 lakks respectively. Consolidated finance costs for current year and current quarter includes exchange (loss) on revaluation of foreign currency borrowings amounting to Rs. (124.12) lakks and Rs. (207.51) lakks respectively. (532.78) 281.14 279.13 (462.54)

8 Deferred tax expense for the current year include MAT Credit entitlement of Rs. 320.41 lakhs.

9 Out of the net proceeds of Re 14,587.17 lakh, pursuant to QIP issue on November 23, 2017, the Company has utilized the proceeds as per the objects of the issue as follows: 9,812.05 apital expenditure including capital advances westments in / loans to subsidiaries Seneral corporate purposes

14,587.18

10 The Company has invested Rs. 56.01 takh in the share capital of Selentus North America Inc., its wholly owered subsidiary Company (the subsidiary) and given a loan of Rs. 255.64 takh to it upto March 31, 2019.
The subsidiary has negative net worth as at March 31, 2019 and is dependent upon the Company to enable it to meet its obligations as they become due. Based on the Proposed plans for the subsidiary, management believes the thorat no feet in the interest in the share capital of the subsidiary, management 12 consolidated for Schene. Both sands and an advantage of the state of t

Place: Mumbai Date: May 24, 2019





Camlin Fine Sciences Ltd. F/II-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400093, India.





+91 22 2832 4404



corporate@camlinfs.com



ASSETS	(Rsi .03.2019 31.0 .03.2019 31.0 .04.2019 31.0 .04.2019 31.0 .04.2019 31.0 .05.364.48 1.207.19 .05.364.48 1.207.19 .05.443.31 4.207.19 .05.452.2019 2.2019
ASSETS 31.03.2019 31.03.2018 31	.03.2019 31.0 udited) (Au 20,854.45 20 5,364.48 1, 207.19 4,443.31 4, 1,739.29 2, 535.84 13.36
ASSETS (Audited) (Audited) (Audited)	udited) (Au 20,854.45 20 5,364.48 1, 207.19 4,443.31 4, 1,739.29 2, 535.84 13.36
(1) Non-Current Assets Froperty, Plant and Equipment Capital work-in-progress 7,892.90 6,834.83 2 (d) Goodwill 207.19 207.19 207.19 (d) Goodwill 207.19 207.19 207.19 (e) Other Intangible Assets Intangible Assets under development 1,610.46 781.10 1 (i) Financial Assets (ii) Loans 6,571.95 4,000.71 (ii) Deferred tax assets (net) 1 1 1 1 1 1 1 1 1	20,854.45 20, 5,364.48 1, 207.19 4,443.31 4, 1,739.29 2, 535.84 13.36
(a) Property, Plant and Equipment 7,892.90 6,834.83 2 (c) Investment Property (d) Goodwill 207.19 207.19 (d) Goodwill 207.19 207.19 (e) Other Intangible Assets Intangible Assets under development 1,610.46 781.10 Investment in associate (i) Investment in associate (ii) Loans (iii) Loans (iv) Deferred tax assets (net) 2,878.17 1,884.96 (ii) Income tax assets (net) 120.70 168.02 (iii) Income tax assets (net) 120.70 168.02 (iv) Income tax assets (net) 120	5,364.48 207.19 4,443.31 1,739.29 535.84 13.36
(c) Capital work-in-progress 7,832.90 6,834.83 2	5,364.48 207.19 4,443.31 1,739.29 535.84 13.36
(c) Investment Property 5,237.16 1,202.84 (d) Goodwill 207.19 207.19 (e) Other Intangible Assets Under development Intangible Assets under development Interest Interest Interest Interest Interest Interest Investment In associate (i) Investments (ii) Loans 6,571.95 4,000.71 (i) Deferred tax assets (net) 2,878.17 1,884.96 (ii) Income tax assets (net) 120.70 168.02 (iii) Income tax assets (net) 120.70 168.02 (iii) Income tax assets (net) 120.70 168.02 (iii) Income tax assets (net) 120.70 168.02 (iiii) Income tax assets (net) 120.70 168.02 (iiii) Income tax assets (net) 120.70 168.02 (iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii	5,364.48 207.19 4,443.31 1,739.29 535.84 13.36
(d) Goodwill (207.19 207.19 207.19 (e) Other Intangible Assets Intangible Assets under development (315.83 Investment in associate (i) Investments (ii) Loans (571.95 4,000.71 (i) Deferred tax assets (net) (2,878.17 1,884.96 (ii) Income tax assets (net) (10,000.71	5,364.48 207.19 4,443.31 4, 1,739.29 535.84 13.36
(e) Other Intangible Assets (f) Intangible Assets under development	4,443.31 4, 1,739.29 2, 535.84 13.36
(f) Intangible Assets under development	1,739.29 535.84 13.36
(g) Intangible Assets under development 1.5.83 1.610.46 781.10 Investment in associate 1.610.46 781.10 Investments 1.00.71 1.0	1,739.29 535.84 13.36
(h) Financial Assets (ii) Investments (iii) Loans (6,571.95 4,000.71 (iii) Deferred tax assets (net) (120.70 168.02 (iii) Income tax assets (net) (120.70 168.02 (iii) Income tax assets (net) (120.70 168.02 (iii) Income tax assets (net) (120.70 168.02 (iiii) Income tax assets (net) (120.70 168.02 (535.84 13.36
(i) Investments 6,571.95 4,000.71 (ii) Deferred tax assets (net) 120.70 168.02 4 (iii) Income tax assets 120.70 168.02 4 (iv) Other non-current assets 338.36 282.86 (iv) Other non-current Assets 2,400.44 485.40 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
(i) Investments 6,571.95 4,000.71 (ii) Deferred tax assets (net) 120.70 168.02 4 (iii) Income tax assets 120.70 168.02 4 (iv) Other non-current assets 338.36 282.86 (iv) Other non-current Assets 2,400.44 485.40 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	71100
(ii) Loans 6,571,95 4,000.71 (i) Deferred tax assets (net) 2,878,17 1,884,96 (ii) Income tax assets 120,70 168,02 4 (iv) Other non-current assets 358,36 282,86 (iv) Total Non-current Assets 27,344,13 15,965,74 15	71100
(i) Deferred tax assets (net) 2,878.17 1,884.96 (ii) Income tax assets 120.70 168.02 (iv) Other non-current assets 2,400.44 13 15.96.740 17 (iv) Deferred tax assets 120.70 168.02 (iv) Other non-current assets 2,400.44 13 15.96.740 17 (iv) Other non-current Assets 127.344 13 15.96.740 17 (iv) Other non-current Assets	
01 Income tax assets 120.70 168.02 48 120.70 168.02 49 120.70 168.02 49 120.70 168.02 49 120.70 168.02 49 120.70 120.7	714.25
(k) Other non-current assets 358.36 282.86 7 Total Non-current Assets 2,400.44 485.40 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1,113.84
1 otal Non-current Assets 27,344 13 15 963 74 485.40 1	1,124.60 3,9
27,344.13 15,062.74 44	739.69
	,581.35 4
Current Assets	,431.65 35,0
(a) Inventories	
(b) Financial assets 10,930.99 11,481.27 28	,541.39 23.9
(i) Investments	,541.39 23,9
(ii) Trade receivables 325.49 10.807.63	325.49 10.80
(iii) Cash and cash equivalents 26,185.91 21.142.14 20	10,0
(iv) Other bank balances 1,889.04 179.32 5,	
(v) Loans 5,023.02 959.83 5	0
(vi) Other financial assets 1,613.34 2,340.80	023.02 96 307.14 34
(c) Other current assets 2,211.80 1,924.45 1	074.75 62
Total Current Assets 2,572.75 2,978.88 5	722.51 5,53
TOTAL ASSETS 50,752.34 51,814.32 67.	247.64 66,55
78,096.47 67,778.06 1.08.6	579.29 1,01,64
EQUITY AND LIABILITIES	2/01/01
EQUITY	
(a) Equity Share Capital	1
(b) Other Equity 1,212.54 1,212.30 1,2	12.54 1,213
(c) Non-Controlling Interest 33,530.11 31,933.54 35,8	75.57 35,903
Total Equity 5,9	39.91 6,221
34,742.65 33,145.84 43,0	28.02 43,338
LIABILITIES 45,0	-5/000
Non-current Liabilities (a) Financial Liabilities	
(h) D	
	66.88 196.
	1.84
11 660 04	7.39
Current Liabilities 11,662.94 1,817.32 18,91	4.62 11,220.
a) Financial Liabilities	
(i) Borrowings	
	7.45
(II) Trade Payables 20,029.44 24,69	7.47 24,678.6
(A) Total outstanding dues of micro enterprises and small enterprises; and 400.09 45.88 400	
	0.09 45.8
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 11,373.30 16,675	
micro enterprises and small enterprises 10,188.82 11,373.30 16,675	5.59 17,733.1
(iii) Other financial list the	
(III) Other financial liabilities	
Other current liabilities Other current liabilities Other current liabilities 977.23 967.22 3,481	- 1007.5
(III) Other financial liabilities	.04 847.1

164

TOTAL EQUITY AND LIABILITIES

Current tax liabilities (net)
Total Current Liabilities

FOR CAMLIN FINE SCIENCES LIMITED

35.86 28.37

32,814.90

67,778.06

Ashish S. Dandekar Managing Director

146.09 29.74 48.78

31,690.88

78,096.47

Place: Mumbai Date: May 24, 2019

Registered Office:

Camlin Fine Sciences Ltd. F/II-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400093, India. CIN: L74100MH1993PLC075361

+91 22 6700 1000

+91 22 2832 4404

corporate@camlinfs.com



48.78

46,736.65

1,08,679.29

3,057.34 847.13 700.48 28.37 **47,090.93**

1,01,649.82

CHARTERED ACCOUNTANTS

Auditor's Report on Quarterly and Annual Standalone Financial Results Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors Camlin Fine Sciences Limited F/11-12, WICEL, Opposite SEEPZ Central Road, Andheri (East), Mumbai – 4000093.

- 1. We have audited the accompanying Standalone Financial Results of Camlin Fine Sciences Limited ("the Company") for the quarter and year ended March 31, 2019 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. These quarterly and annual standalone financial results have been prepared on the basis of the standalone financial statements, which are the responsibility of the Company's Management. Our responsibility is to express an opinion on these standalone financial results based on our audit of such standalone financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, and other accounting principles generally accepted in India. Attention is drawn to the fact that the figures for the quarters ended March 31, as reported in these results are the balancing figures between audited figures in respect of the years ended March 31, and the published year to date figures up to the end of the third quarter of the relevant financial year. Also the figures up to the end of the third quarter had only been reviewed and not subjected to audit.
- 2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe our audit provides a reasonable basis for our opinion.
- 3. We draw attention to Note 10 to the Notes to financial results relating to an investment made by the Company in the share capital of Solentus North America Inc., its wholly owned subsidiary company amounting to Rs. 56.01 Lakhs and to whom it has also advanced a loan aggregating to Rs. 255.64 Lakhs. The subsidiary has negative net worth as at March 31, 2019 and is dependent upon the Company to enable it to meet its obligations as they become due. In the opinion of the management, the fall in value of the equity shares is temporary and the recoverability of the above loan is dependent on successful implementation of management's future plans in respect of the said subsidiary.

Our opinion is not modified in respect of the above matter.

LLP IN : AAH - 3437

- 4. In our opinion and to the best of our information and according to the explanations given to us, these quarterly as well as year to date financial results:
 - are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, in this regard; and
 - ii. give a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the profit, total comprehensive income and other financial information for the quarter and year ended March 31, 2019.

For KALYANIWALLA & MISTRY LLP CHARTERED ACCOUNTANTS Firm Registration Number 104607W/W100166

FARHAD M. BHESANIA

PARTNER

Membership Number 127355

Place: Mumbai Date: May 24, 2019

CHARTERED ACCOUNTANTS

Auditor's Report on Quarterly and Annual Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

The Board of Directors Camlin Fine Sciences Limited F/11-12, WICEL, Opposite SEEPZ Central Road, Andheri (East), Mumbai – 4000093.

(gh

- 1. We have audited the accompanying Statement of Consolidated Financial Results of Camlin Fine Sciences Limited ("the Company"), and it's subsidiaries (the Company and it's subsidiaries together referred to as the "Group") and an associate for the quarter and year ended March 31, 2019 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. These quarterly and annual consolidated financial results have been prepared on the basis of consolidated financial statements, which are the responsibility of the Company's Management. Our responsibility is to express an opinion on these consolidated financial results based on our audit of such consolidated financial statements, which have been prepared in accordance with the Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, and other accounting principles generally accepted in India. Attention is drawn to the fact that the figures for the quarters ended March 31, as reported in these results are the balancing figures between audited figures in respect of the year ended on March 31, and the published year to date figures up to the end of the third quarter of the relevant financial years. Also the figures up to the end of the third quarter had only been reviewed and were not subjected to audit.
- We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
- 3. We did not audit the financial results of eleven subsidiaries incorporated outside India and a subsidiary in India included in the consolidated quarterly and annual consolidated financial results, whose consolidated financial statements reflect total asset of Rs. 67,494.75 lakhs as at March 31, 2019; as well as the total revenue of Rs. 20,076.97 lakhs and Rs. 75,671.22 lakhs for the quarter and year ended on that date respectively and for an associate whose share of net loss of Rs. 5.88 lakhs, as considered in the consolidated financial results. These financial statements and other financial information have been audited by other auditors whose report has been furnished to us by the Management and our opinion on the quarterly and annual consolidated financial results, to the extent they have been derived from such financial statements is based solely on the report of such other auditors. Our report on the statement is not modified in respect of this matter.


4. These subsidiaries are located outside India whose financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Company's management has converted the financial results of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India (Indian Accounting Standards 'Ind AS'). We have audited these conversion adjustments made by the Company's management. Our conclusion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based on the report of the other auditors and the conversion adjustments made by the management of the Company and audited by us.

Our report on the statement is not modified in respect of these matters.

s. We did not audit the financial results of five subsidiaries incorporated outside India included in the consolidated quarterly and annual consolidated financial results, whose consolidated financial statement reflect total asset of Rs. 1,339.36 lakhs as at March 31, 2019; as well as the total revenue of Rs. 294.31 lakhs and Rs. 374.15 lakhs for the quarter and year ended on that date respectively. These financial results of five subsidiaries are not audited as of the date of this report and have been included in the Unaudited Consolidated Financial Results on the basis of the Unaudited Management Accounts.

Our report on the Statement is not modified in respect of our reliance on the Unaudited Management Accounts and other financial information furnished by the Management.

- 6. Based on our audit and on consideration of report of other auditors as referred to in paragraph 4 above, in our opinion and to the best of our information and according to the explanations given to us, these quarterly and annual consolidated financial results:
 - i. include the quarterly and annual financial results of the following entities:
 - a. CFCL Mauritius Pvt. Ltd.
 - b. CFS do Brasil Indústria, Comércio, Importação e Exportação de Aditivos Alimentícios Ltda.
 - c. Solentus North America Inc
 - d. CFS Europe S.P.A
 - e. CFS North America LLC
 - f. Dresen Quimica SAPI De C.V.
 - g. Industrias Petrotec De Mexico S.A. de C.V.
 - h. Nuvel, S.A.C.
 - i. Britec, S.A
 - j. Inovel, S.A.S.
 - k. Grinel, S.A
 - 1. CFS International Trading (Shanghai) Ltd
 - m. Chemolutions Chemicals Ltd.
 - n. CFS Wanglong Flavours (Ningbo) Co. Ltd.
 - o. CFS Pahang Asia Pte. Ltd.
 - p. CFS Argentina S.A.
 - q. CFS Chile S.p.A
 - r. Fine Lifestyle Brands Ltd.





iii. give a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated profit, consolidated total comprehensive income and other financial information of the Group for the quarter as well as for the year ended March 31, 2019.

For KALYANIWALLA & MISTRY LLP CHARTERED ACCOUNTANTS Firm Registration Number 104607W/W100166

FARHAD M. BHESANIA

PARTNER

Membership Number 127355

Place: Mumbai Dated: May 24, 2019





The above information is an extract of the detailed format of __audited results for the quarter and year ended March 31, 2019 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations Pland Disclosure Requirements) Regulations, 2015. The full format of the __audited results for the quarter and year ended March 31, 2019 are available on the Company's website, www.camlinfs.com and the Stock Sexchange websites i.e. www.beeindia.com and www.nseindia.com and www.nseindia.com and www.nseindia.com and www.nseindia.com and the Stock Sexchange websites i.e. www.beeindia.com and www.nseindia.com and www.nseindia.com and the Stock Sexchange websites i.e. www.beeindia.com and www.nseindia.com and www Ashish S. Dandekar Managing Director

(3.07)

0.05

(0.66)

(0.17)

0.60

(1.67)

0.88

(0.26)

(0.44)

0.22

Total Comprehensive Income for the period Equity Share Capital Reserves (excluding revaluation reserves as shown in the Balance Sheet of previous year) Earnings per share (before and after extraordinary items) (of Re 1/-each)
-Basic Rs. Net Profit/(Loss) from ordinary activities after tax Net Profit/(Loss) for the period after tax and nonontrolling interests (after extraordinary items) otal Income from Operations Diluted Rs. No. Registered Office

Camlin Fine Sciences Ltd. 7/11-12 CIN: L74100MH1993PLC075361



Date: May 24, 2019

(Rs.in Lakh)

31.03.2019 31.03.2018

31.03.2018 (Audited)

31.03.2019 31.12.2018

31.03.2019 31.03.2018

31.03.2018 (Audited)

31.12.2018

31.03.2019

PARTICULARS

(Unaudited)

(Audited)

YEAR ENDED

(Unaudited)

(Audited)

(Audited)

YEAR ENDED

CONSOLIDATED

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2019

STANDALONE

QUARTER ENDED

QUARTER ENDED

(Audited)

(Audited)

(2,397.22)(2,964.31)

89,216.67

23,168.70 (425.88) (309.92) 169.62

24,139.88 (78.83) (203.56)

> 629.88 727.22 944.09

26,803.53 (Audited)

> 40,502.79 (1,417.87) (1,417.87) (1,405.44)

> > 1,072.82 1,072.82 1,042.70

12,818.49 122.07

14,993.86 (533.65) (533.65) (565.61)

17,151.18 265.32 (1,160.71)

353.91

(521.71)

1,212.54

147.28 1,212.30

1,212.54

273.58

1,212.54



Annexure -2

The Board on the recommendation of the Nomination and Remuneration Committee are recommending the appointment of Mr. Amol Shah (DIN: 00171006), as an Independent Director to the shareholders at the ensuing 26^{th} Annual General Meeting of the Company for the term of 5 (five) years from the date of the 26^{th} Annual General Meeting.

Mr. Amol Shah graduated as Bachelor of science in engineering from University of Kent, Canterbury. He pursued his MBA from University of Southern California. He is also an alumnus of the prestigious Harvard Business School where he pursued an OPM (Owners, Proprietors & Managers) course. He has played a pivotal role in the management and growth of the MJ Group. With his focus on effective management strategies & his marketing prowess, he has driven MJ group towards achieving new heights across businesses. MJ is a multi faceted, multi dimensional business Group with manufacturing activities covering Human Healthcare, Flavors/Fragrances compounds, Plant protection and water treatment chemicals and has manufacturing locations in Maharashtra and Gujarat in India, and Dubai in the UAE, and with offices in London, Uzbekistan and Moscow.

Mr. Shah is Managing Director of the MJ Group and he possesses more than 25 years of experience in the industry. Mr. Shah does not hold any shares in the Company and is not related to any of the Directors.



Registered Office:

Camlin Fine Sciences Ltd. F/II-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400093, India. CIN: L74100MH1993PLC075361







